Timothy Langer
Director Financiero/CFO en Myst Therapeutics LLC .
Fortuna: 2 M $ al 31/05/2024
Perfil
Timothy J.
Langer is associated with Myst Therapeutics LLC as the Chief Financial Officer.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
13/05/2024 | 777 657 ( 3.36% ) | 2 M $ | 31/05/2024 |
Cargos activos de Timothy Langer
Empresas | Cargo | Inicio |
---|---|---|
Myst Therapeutics LLC
Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Director Financiero/CFO | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Myst Therapeutics LLC
Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Commercial Services |
- Bolsa de valores
- Insiders
- Timothy Langer